Johnson & Johnson is set to begin listing four prescription medicines on the Trump administration’s TrumpRx website, expanding the government-backed discount drug platform as the White House pushes its “most-favoured nation” pricing model. CBS News reported on April 24 that the company’s medicines will start appearing on the site on Friday.
According to CBS, the four drugs are metformin, metformin extended release, Invokana and Xarelto. The move follows Johnson & Johnson’s January agreement with the Trump administration, under which the company agreed to participate in TrumpRx and provide patients access to its medicines at significantly reduced prices, while also securing an exemption from certain pharmaceutical tariffs.
Johnson & Johnson said at the time that the arrangement was aimed at improving access to medicines and lowering costs for U.S. patients. In its January 8 statement, the company said it would align pricing more closely with rates paid in other developed countries, alongside a planned $55 billion investment in U.S. manufacturing, research and technology over four years.
The addition of J&J’s drugs gives the administration another major pharmaceutical partner for TrumpRx, which was launched in February as a federal portal directing patients to discounted brand-name medicines. The White House has described the programme as a step toward bringing U.S. drug prices closer to those in peer countries and delivering some of the “lowest prices” on prescription medicines.
However, the programme’s scope remains limited. CBS reported that listed prices are primarily aimed at uninsured patients or those who must pay out of pocket when insurance does not cover their medication. Independent reports have also noted that TrumpRx covers only a small portion of the market, and in some cases, medicines may still be available more cheaply elsewhere, particularly where generic alternatives exist.
This makes Johnson & Johnson’s participation politically significant, but its real impact will depend on whether the listed drugs provide meaningful savings for patients most affected by high prescription costs. For now, it represents another step in the administration’s effort to bring major pharmaceutical companies onto the platform ahead of broader questions about its long-term effectiveness.
